Leading healthcare solutions company in Asia, Zuellig Pharma, on November 30, 2025, confirmed through an announcement the grand opening of its new state-of-the-art Clinical Trial Support – CTS Innovation Center based in South Korea.
Interestingly, the opening of this facility highlights the continued investment as well as commitment by Zuellig Pharma so as to advance healthcare and hence reinforce its position as a dependable regional partner when it comes to driving meaningful results for patients, partners as well as communities throughout the region.
Strategically located nearby the Gyeongbu Expressway in the Gyeonggi-do province, the new 3,800-square-meter facility is going to redefine benchmarks when it comes to clinical trial logistics by way of automation, digitalization as well as strict Good Practice – GxP compliance. It is designed to elevate the operational efficiency, scalability, and also dependability throughout the diverse therapeutic aspects.
According to Zuellig Pharma’s CEO John Graham, as part of an integrated healthcare solutions company, this landmark goes on to mark a major step forward for the company so as to remain agile and responsive to the ever-changing clinical trial spectrum. It also goes on to reflect the continued commitment by Zuellig Pharma to advance healthcare via innovation and, of course, sustainable infrastructure, therefore creating greater access in terms of treatments and simultaneously rolling out some meaningful outcomes for partners as well as the communities they serve.
The facility comes equipped with certain advanced capabilities that set new benchmarks in terms of clinical trial logistics. It features a completely automated order fulfillment system, which elevates the speed and precision as well as the dependability when it comes to clinical supply delivery. Its agile as well as scalable architecture ensures operations that are uninterrupted, while robust cybersecurity measures that are already in place safeguard the sensitive clinical trial data.
Besides, the facility also offers comprehensive temperature-zone support, therefore helping Zuellig Pharma to go ahead and manage thousands of distinct clinical trial SKUs, and that too under strict ambient, frozen, cold, deep frozen, and cryogenic as well as return storage conditions. This makes sure that the temperature-sensitive products get handled with the highest levels of accuracy all across the entire supply chain.
The facility, which is designed with precision and also has a specialized repackaging infrastructure, is constructed so as to accommodate controlled environments that are customized to ambient, cold, and frozen as well as amber light repackaging specifications. These environments indeed meet the strict clinical and regulatory benchmarks leading to the maintenance of the integrity of the product all across the clinical trial lifecycle. Moreover, an integrated end-to-end tracking as well as monitoring system offers a complete chain-of-custody, full traceability, and also adherence to GxP needs, hence reinforcing quality and also compliance come what may at any stage.
According to Zuellig Pharma’s SVP, Clinical Trial Support Business Unit Lead, Giuseppe Leo, as of 2025, South Korea is among the top 10 clinical trial markets in the world and holds the distinction of having the third-largest number of R&D pipelines across the world. He added that their new facility has been built in order to meet up with this rising demand, thereby redefining how investigational products get stored and managed as well as distributed. With accuracy levels in mind, they look to enable the very dependable delivery when it comes to critical therapies in order to enhance the patient access as well as outcomes the world over.
Throughout 2024, the center has gone ahead and supported more than 3,000 cumulative studies in partnership with over 100 clients, thereby managing a yearly volume of almost 13,000 outbound shipments, which includes the likes of chemicals, medical devices, and biologics, as well as cellular and gene therapies. Its wide track record goes on to include partnerships with 14 of the top 20 pharmaceutical companies of the world and also 8 of the top 10 global CROs, hence highlighting its position as a dependable partner when it comes to clinical trial research across the world.
